Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 928

Sort by

Sort Order Select

Journal Articles

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

Diana Hanekamp, Lok Lam Ngai, Jeroen J. W. M. Janssen, Arjan van de Loosdrecht, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2021) 137 (12): 1694–1697.

https://doi.org/10.1182/blood.2020007150

Published: 2021

Includes: Supplemental data

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

How I diagnose and treat NPM1 -mutated AML

Brunangelo Falini, Lorenzo Brunetti, Maria Paola Martelli

Blood (2021) 137 (5): 589–599.

https://doi.org/10.1182/blood.2020008211

Published: 2021

Journal Articles

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

Robert P. Hasserjian, David P. Steensma, Timothy A. Graubert, Benjamin L. Ebert

Blood (2020) 135 (20): 1729–1738.

https://doi.org/10.1182/blood.2019004770

Published: 2020

Journal Articles

How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

Alexandros Spyridonidis

Blood (2020) 135 (19): 1639–1649.

https://doi.org/10.1182/blood.2019003566

Published: 2020

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Jeffrey Teoh, PhD, Timothy G. Johnstone, PhD, Brian Christin, BS, Rachel Yost, Neil A. Haig, Mary Mallaney, Aditya Radhakrishnan, Heidi H. Gillenwater, MD, Tina Albertson, MD, Paul Guptill, Lauren F. Brown, Christopher G. Ramsborg, Ronald J. Hause, PhD, Ryan P. Larson, PhD

Blood (2019) 134 (Supplement_1): 593.

https://doi.org/10.1182/blood-2019-127150

Published: 2019

Journal Articles

Post-Treatment FDG-Avid Splenic Lesions in DLBCL: Clinical and Radiographic Characteristics for Risk Assessment

Boaz Nachmias, MD PhD, Geremy Godefroy, MD, Chezi Ganzel, MD, Neta Goldschmidt, MD, Eyal Rozenbach, MD, Rachel Bar-Shalom, MD, Diana Libster, MD, Vladimir Vainstein, MD

Blood (2019) 134 (Supplement_1): 5358.

https://doi.org/10.1182/blood-2019-121473

Published: 2019

Journal Articles

Curriculum in Chronic Lymphocytic Leukemia Narrows the Educational Gaps of the Oncology Healthcare Team

Lauren Willis, PharmD, Lisa Brauer, PhD, Emily S Van Laar, MS, Patrick Kugel, MBA, Katie S Lucero, PhD MS, BS, John N. Allan, MD, Farrukh T. Awan, MD, Danielle M. Brander, MD, Jonathon B. Cohen, MDMS, Jacqueline C Barrientos, MD

Blood (2019) 134 (Supplement_1): 5878.

https://doi.org/10.1182/blood-2019-124808

Published: 2019

Journal Articles

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Allison Pike, RN, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 5906.

https://doi.org/10.1182/blood-2019-127272

Published: 2019

Journal Articles

Education and Promotion of MRD Testing within the Multidisciplinary Cancer Care Team for Adults with Acute Lymphoblastic Leukemia in the Community Setting

Monique D. Dawkins, EdD, Firas El Chaer, MD, Leigh Boehmer, PharmD, Ashkan Emadi, MD, Elias Jabbour, MD, Jeffrey Kendall, PsyD, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Sandra Kurtin, PhD, ANP-C, AOCN, Mohamed Hersi, PharmD, Meredith Barnhart, LCSW-R

Blood (2019) 134 (Supplement_1): 5834.

https://doi.org/10.1182/blood-2019-123461

Published: 2019

Journal Articles

Genomic Analysis of Hodgkin Lymphoma

Ralf Küppers, PhD

Blood (2019) 134 (Supplement_1): SCI-7.

https://doi.org/10.1182/blood-2019-121073

Published: 2019

Journal Articles

Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib

Cheryl A Cohler Peretz, MD, Lisa H F McGary, Tanya F Kumar, J Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, PhD, Chunxiao Zhang, Mark J. Levis, MD, Alexander E. Perl, MD, Anskar Yu Hung Leung, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1440.

https://doi.org/10.1182/blood-2019-132105

Published: 2019

Journal Articles

Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)

Matthew C Foster, MD, Yuri Fedoriw, MD, Will Pulley, BA, Joshua Zeidner, MD, Catherine C. Coombs, MD, Emily Mirkin, Maryam Zomorrodi, Rachel Toughiri, PhD, Alena Bartakova, MD, Craig Carson, PhD, Rolf Muller, PhD, Paul M. Armistead, MD PhD

Blood (2019) 134 (Supplement_1): 1417.

https://doi.org/10.1182/blood-2019-127434

Published: 2019

Journal Articles

Detection of Measurable Residual Disease May Better Predict the Outcome Rather Than Mutations Based on Next-Generation Sequencing in Acute Myeloid Leukemia with Biallelic Mutations of CEBPA

Jing Wang, MD, Hao Jiang, Xiaojun Huang, MD, Guorui Ruan, Run-Qing Lu

Blood (2019) 134 (Supplement_1): 1449.

https://doi.org/10.1182/blood-2019-127696

Published: 2019

Journal Articles

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3- itd Mutation

Blood (2019) 134 (Supplement_1): 1421.

https://doi.org/10.1182/blood-2019-127937

Published: 2019

Journal Articles

Patient-Tailored Deep Sequencing of Peripheral Blood Enables Early Detection of Relapse in Childhood Acute Myeloid Leukemia

Kristian Løvvik Juul-Dam, MD, Erik Delsing Malmberg, Anna Rehammar, Erik Kristiansson, Jonas Abrahamsson, Anni Aggerholm, Marta Maria Dirdal, Kirsi Jahnukainen, Birgitte Lausen, Hans Beier Ommen, Henrik Hasle, Linda Fogelstrand

Blood (2019) 134 (Supplement_1): 1456.

https://doi.org/10.1182/blood-2019-124970

Published: 2019

Journal Articles

Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Genevieve Alcorn, Mary-Elizabeth M. Percival, MD, Emily M Huebner, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Vivian G. Oehler, MD, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1364.

https://doi.org/10.1182/blood-2019-123542

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

DARTs point the way forward in AML

How I diagnose and treat NPM1 -mutated AML

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Post-Treatment FDG-Avid Splenic Lesions in DLBCL: Clinical and Radiographic Characteristics for Risk Assessment

Curriculum in Chronic Lymphocytic Leukemia Narrows the Educational Gaps of the Oncology Healthcare Team

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Education and Promotion of MRD Testing within the Multidisciplinary Cancer Care Team for Adults with Acute Lymphoblastic Leukemia in the Community Setting

Genomic Analysis of Hodgkin Lymphoma

Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib

Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)

Detection of Measurable Residual Disease May Better Predict the Outcome Rather Than Mutations Based on Next-Generation Sequencing in Acute Myeloid Leukemia with Biallelic Mutations of CEBPA

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3- itd Mutation

Patient-Tailored Deep Sequencing of Peripheral Blood Enables Early Detection of Relapse in Childhood Acute Myeloid Leukemia

Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only